Clinical malaria · non‐immune adults and children travelling to or living in malaria‐endemic settings
1 finding from 1 review
Vomiting · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in vomiting compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Abdominal pain · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in abdominal pain compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Diarrhoea · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in diarrhoea compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Headache · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in headache compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Dizziness · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher dizziness compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Pruritis · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in pruritis compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Visual impairment · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in visual impairment compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Mouth ulcers · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in mouth ulcers compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Serious adverse effects · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in serious adverse effects compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Discontinuation of medication due to adverse events · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher discontinuation of drug due to adverse effects compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Abnormal dreams · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher abnormal dreams compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Insomnia · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher insomnia compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Anxiety · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher anxiety compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Depressed mood · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher depressed mood compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Abnormal thoughts or perceptions · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in abnormal thoughts or perceptions compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Nausea · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher nausea compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review